Joshua Schimmer
Stock Analyst at Cantor Fitzgerald
(1.21)
# 3,329
Out of 4,670 analysts
27
Total ratings
50%
Success rate
-11.92%
Average return
Main Sectors:
Stocks Rated by Joshua Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio | Reiterates: Overweight | $50 | $1.87 | +2,573.80% | 4 | Apr 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Reiterates: Overweight | $50 | $44.73 | +11.78% | 2 | Nov 15, 2023 | |
| OTIS Otis Worldwide | Maintains: Equal-Weight | $91 → $92 | $101.20 | -9.09% | 4 | Jul 27, 2023 | |
| RNA Avidity Biosciences | Downgrades: In-Line | $20 | $43.25 | -53.76% | 1 | Mar 31, 2023 | |
| BNOX Bionomics | Upgrades: Outperform | $6 | $0.29 | +1,937.35% | 2 | Mar 10, 2023 | |
| NBIX Neurocrine Biosciences | Upgrades: Outperform | $130 | $125.65 | +3.46% | 1 | Mar 3, 2023 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $80 → $50 | $24.69 | +102.51% | 1 | Feb 28, 2023 | |
| TGTX TG Therapeutics | Maintains: Outperform | $16 → $25 | $35.07 | -28.71% | 3 | Jan 24, 2023 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $65 → $75 | $14.11 | +431.54% | 1 | Sep 30, 2022 | |
| BMRN BioMarin Pharmaceutical | Upgrades: Outperform | $90 → $100 | $64.26 | +55.62% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $738.00 | - | 2 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $86 → $100 | $0.35 | +28,463.27% | 2 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $71.72 | +18.52% | 3 | May 31, 2018 |
Cabaletta Bio
Apr 5, 2024
Reiterates: Overweight
Price Target: $50
Current: $1.87
Upside: +2,573.80%
Mirum Pharmaceuticals
Nov 15, 2023
Reiterates: Overweight
Price Target: $50
Current: $44.73
Upside: +11.78%
Otis Worldwide
Jul 27, 2023
Maintains: Equal-Weight
Price Target: $91 → $92
Current: $101.20
Upside: -9.09%
Avidity Biosciences
Mar 31, 2023
Downgrades: In-Line
Price Target: $20
Current: $43.25
Upside: -53.76%
Bionomics
Mar 10, 2023
Upgrades: Outperform
Price Target: $6
Current: $0.29
Upside: +1,937.35%
Neurocrine Biosciences
Mar 3, 2023
Upgrades: Outperform
Price Target: $130
Current: $125.65
Upside: +3.46%
Denali Therapeutics
Feb 28, 2023
Maintains: Outperform
Price Target: $80 → $50
Current: $24.69
Upside: +102.51%
TG Therapeutics
Jan 24, 2023
Maintains: Outperform
Price Target: $16 → $25
Current: $35.07
Upside: -28.71%
Rocket Pharmaceuticals
Sep 30, 2022
Maintains: Outperform
Price Target: $65 → $75
Current: $14.11
Upside: +431.54%
BioMarin Pharmaceutical
Mar 1, 2021
Upgrades: Outperform
Price Target: $90 → $100
Current: $64.26
Upside: +55.62%
Feb 25, 2020
Upgrades: Outperform
Price Target: n/a
Current: $738.00
Upside: -
Feb 3, 2020
Upgrades: Outperform
Price Target: $86 → $100
Current: $0.35
Upside: +28,463.27%
May 31, 2018
Assumes: Overweight
Price Target: $85
Current: $71.72
Upside: +18.52%